Ocean Biomedical, Inc.
Close on Oct 19, 2026
- Market cap
- $45.51K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Ocean Biomedical has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Ocean Biomedical filed with the SEC
Biomedical Expands into Energy and Digital Asset Sectors to Accelerate Growth and Shareholder Value
Listing notice · Executive or director change · Other events · EX-99.1 to Form 8-K
Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
OCEAN BIOMEDICAL, INC. ANNOUNCES RECEIPT OF NOTICE FROM NASDAQ REGARDING LATE FILING OF QUARTERLY REPORT ON FORM 10-Q
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
OCEAN BIOMEDICAL, INC. ANNOUNCES RECEIPT OF NOTICE FROM NASDAQ REGARDING LATE FILING OF ANNUAL REPORT ON FORM 10-K
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED NOVEMBER 29, 2023
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
OCEAN BIOMEDICAL AND VIRION THERAPEUTICS FORM JOINT VENTURE SUPPORTING MULTI-NATIONAL, FIRST-IN-HUMANS CLINICAL CHRONIC HEPATITIS B STUDY: NOW ENROLLING, WITH GOAL OF A FUNCTIONAL CURE FOR A DISEASE AFFECTING 300+ MILLION PATIENTS WORLDWIDE
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
OCEAN BIOMEDICAL ANNOUNCES LOAN COMMITMENT FROM LARGEST STOCKHOLDER; UP TO $10 MILLION
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Biomedical Debuts as Publicly Traded Company Focused on Accelerating the Commercialization of Innovative Assets from Research Universities
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED FEBRUARY 9, 2023
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
and Ocean Biomedical Announce Shareholder Approval of Business Combination
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Measures regarding Excise Tax
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biomedical and Aesther Healthcare Acquisition Corp. Announce Publication of Discovery Data for a Major Anti-Tumor Pathway in
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biomedical Provides Corporate Update and Company Summary
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JANUARY 13, 2023.
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Healthcare Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Business Combination
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Healthcare Acquisition Corp. Announces Intention to Extend Period to Consummate Business Combination
Material agreement · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K/A
Regulation FD disclosure · EX-99.1 to Form 8-K/A
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Malaria Drug Discovery Presented at the ASTMH Tropical Medicine Meeting by Ocean Biomedical’s Scientific Co-founder, Dr. Jake Kurtis,
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
on Their Innovative mRNA Vaccine Program, Ocean Biomedical, Inc. and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA) Recently Announced
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Healthcare Acquisition Corp. Announces Intention to Extend Period to Consummate Business Combination
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Healthcare Acquisition Corp (NASDAQ: AEHA) and Ocean Biomedical, Inc. Announce $75 Million Common Stock Purchase Transaction with White
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Antibodies and Immune Checkpoint Inhibitors Which Kill Glioblastoma and Block the Metastasis of Malignant Melanoma Cells to the Lung
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a Next-Generation Biopharma
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Healthcare Acquisition Corp. and United Gear & Assembly, Inc. (High Precision Gears for Electric Vehicles) Announce Definitive Merger
Regulation FD disclosure · EX-99.1 to Form 8-K